![Christoph Massner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christoph Massner
Direttore/Membro del Consiglio presso
Ariceum Therapeutics GmbH
Profilo
Christoph Massner holds the position of Non-Executive Director at Ariceum Therapeutics GmbH.
Since 2018, Dr. Massner has been a Partner at Bek Venture, with the title starting in 2025.
Posizioni attive di Christoph Massner
| Società | Posizione | Inizio |
|---|---|---|
Earlybird Venture Capital GmbH & Co. KG
 Earlybird Venture Capital GmbH & Co. KG Investment ManagersFinance Bek Ventures invests in companies located across the Europe. The firm targets companies operating in the fields of tech-enabled businesses in fintech/insurtech, enterprise software, and deep tech. It provides financing for early and growth stage capital requirements with an investment size of EUR 0.5 - 10 million. | Analista di Private Equity | 01/05/2018 |
Ariceum Therapeutics GmbH
 Ariceum Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Develops novel targeted radiopharmaceuticals for treatment of cancer | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
61
Relazioni di 1° grado
2
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Earlybird Venture Capital GmbH & Co. KG
Earlybird Venture Capital GmbH & Co. KG Investment ManagersFinance Bek Ventures invests in companies located across the Europe. The firm targets companies operating in the fields of tech-enabled businesses in fintech/insurtech, enterprise software, and deep tech. It provides financing for early and growth stage capital requirements with an investment size of EUR 0.5 - 10 million. | Finance |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Develops novel targeted radiopharmaceuticals for treatment of cancer | Health Technology |
